Targeting a key factor to treat breast cancers
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers
This study is looking at how breast cancer cells fix their damaged DNA to survive and resist treatments, especially in tougher types like triple-negative and estrogen receptor-positive breast cancer, with the goal of finding ways to make current therapies work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10977311 on NIH RePORTER |
What this research studies
This research investigates how breast cancer cells repair DNA damage and how this contributes to their survival and resistance to treatments. It focuses on the role of specific proteins involved in DNA repair pathways, particularly in aggressive forms of breast cancer like triple-negative and estrogen receptor-positive types. By inhibiting these proteins, the research aims to enhance the effectiveness of existing therapies and potentially improve patient outcomes. The approach involves understanding the mechanisms of DNA damage response and developing targeted therapies that can disrupt these processes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with aggressive breast cancer subtypes, such as triple-negative breast cancer or estrogen receptor-positive breast cancer.
Not a fit: Patients with early-stage breast cancer that is not aggressive or those who do not have DNA repair deficiencies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for breast cancer, particularly for patients with aggressive forms of the disease.
How similar studies have performed: Other research has shown promise in targeting DNA repair mechanisms in cancer, indicating that this approach could be a viable therapeutic strategy.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Rao, Manjeet Kumar — University of Texas Hlth Science Center
- Study coordinator: Rao, Manjeet Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.